Clinical trials on trial
By Osagie Obasogie,
The New Scientist
| 01. 22. 2011
[Commentary]
A great deal of scientific research – especially in medicine – relies on human subjects. Protecting volunteers has been a prominent social and legal issue since the 1950s, when the world recoiled from the horrors of Nazi medicine.
We have come a long way since then, but it pays to remember that the Nazis did not have a monopoly on atrocities committed in the name of science. One of the worst cases of human subject abuse was perpetrated by American scientists who, between 1932 and 1972, misled hundreds of black people with syphilis in Tuskegee, Alabama, by deliberately leaving them untreated to enable researchers to study the progression of the disease.
To view the entire article, please click below for version in PDF format.
Related Articles
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Siddhi Mahatole and Mariam E. Sunny, Reuters | 06.13.2025
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' (REGN.O), opens new tab offer for the DNA-testing company in a bankruptcy auction.
Last month, Regeneron agreed to...